Sector pending / Drugs, Drug Proprietaries, and Druggists' SundriesUpdated 2026-05-10 22:07 UTC

FRA/B1S stock hub

FRA/B1S has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

FRA/B1Sis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

356.9M

Frankfurt Stock Exchange

Market data

Price

Recent price action with selectable time range.

FRA/B1SFRA/B1S

—

Loading chart…

In the news

Latest news · FRA/B1S

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/E19.2

P25 n/aP50 n/aP75 n/a

ROE6.3

P25 n/aP50 n/aP75 n/a

ROIC1.5

P25 n/aP50 n/aP75 n/a

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All FRA/B1S market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

195

Groups with data

Currency

CNY

Showing 195 of 195 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Country	Cayman Islands
Country code	DE
Employees	6,620
Employees Change	-143%
Employees Change Percent	-2.11
Enterprise value	EUR 178.7M
Exchange	Frankfurt Stock Exchange
Financial currency	CNY
First seen	2026-05-10
Industry	Drugs, Drug Proprietaries, and Druggists' Sundries
Last refreshed	2026-05-10
Market cap	EUR 356.9M
Price	EUR 0.5
Price currency	EUR
Rev Per Employee	367,402.88x
Sic	5122
Symbol	fra/B1S
Website	https://www.ysbang.cn

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	5.22%
EV Earnings	9.6x
EV/EBIT	25.89x
EV/EBITDA	7.1x
EV/FCF	2.37x
EV/Sales	0.07x
FCF yield	21.17%
P/B ratio	1.23x
P/E ratio	19.16x
P/S ratio	0.14x
PE Ratio3 Y	104.37x
PE Ratio5 Y	659.7x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	0.3%
EBITDA Margin	0.64%
FCF margin	2.96%
Gross margin	11%
Gross Profit	EUR 280.9M
Gross Profit Growth	13.3%
Gross Profit Growth Q	29.06%
Gross Profit Growth3 Y	8.51%
Gross Profit Growth5 Y	7.2%
Net Income	EUR 18.6M
Net Income Growth	409.66%
Net Income Growth Q	813.56%
Net Income Growth3 Y	402.85%
Pretax Margin	0.65%
Profit Margin	0.73%
Profit Per Employee	EUR 2,680
ROA	0.56
Roa5y	-2.85
ROCE	2.37
ROE	6.27
ROIC	1.51

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	-34.06%
EPS Growth	378.3
EPS Growth Q	768.8
FCF Growth	-1.94%
FCF Growth Q	60.94%
FCF Growth3 Y	9.01%
FCF Growth5 Y	2.25%
OCF Growth	-2.77%
OCF Growth Q	60.79%
OCF Growth3 Y	8.12%
OCF Growth5 Y	2.01%
Revenue Growth	17.13x
Revenue Growth Q	22.41x
Revenue Growth3 Y	5.58x
Revenue Growth5 Y	6.2x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	EUR 2.98
Assets	EUR 920.9M
Cash	EUR 212.5M
Current Assets	EUR 748.3M
Current Liabilities	EUR 611.5M
Debt	EUR 39.9M
Debt EBITDA	EUR 1.53
Debt Equity	EUR 0.14
Debt FCF	EUR 0.53
Equity	EUR 290.6M
Interest Coverage	5.29
Liabilities	EUR 630.3M
Long Term Assets	EUR 172.6M
Long Term Liabilities	EUR 18.8M
Net Cash	EUR 172.7M
Net Cash By Market Cap	EUR 48.38
Net Cash Growth	-19.11%
Net Debt EBITDA	EUR -10.58
Net Debt Equity	EUR -0.59
Net Debt FCF	EUR -2.29
Tangible Book Value	EUR 205.4M
Tangible Book Value Per Share	EUR 0.3

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	1.22
Inventory Turnover	11.18
Net Working Capital	EUR -50.8M
Quick ratio	0.41
Working Capital	EUR 133.6M
Working Capital Turnover	EUR 2.13

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-5.71%
Dividend Growth	0%
Dividend Growth Years	1%
Dividend per share	EUR 0.01
Dividend Years	1
Dividend Yield	1.85%
Ex Div Date	2025-05-23
Last Dividend	EUR 0.01
Payout Ratio	33.2%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	-34.04%
200-day SMA	0.77
50-day SMA	0.51
50-day SMA vs 200-day SMA	50under200
All Time High	1.29
All Time High Change	-61.55%
All Time High Date	2025-10-08
All Time Low	0.4
All Time Low Change	24.62%
All Time Low Date	2026-03-10
ATR	0.02
Ch YTD	-14.48
High	0.5
High52	1.29
High52 Date	2025-10-08
High52ch	-61.55%
Low	0.5
Low52	0.4
Low52 Date	2026-03-10
Low52ch	24.62%
Ma50ch	-3.09%
Price vs 200-day SMA	-35.77%
RSI	43.19
RSI Monthly	35.1
RSI Weekly	39.13
Sharpe ratio	-0.46x
Sortino ratio	-0.6
Total Return	-3.86%
Tr YTD	-14.48
Tr1m	-12.21%
Tr1w	-5.52%
Tr3m	-8.99%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Operating Income	EUR 7.7M
Operating margin	0.3

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	332,917,467%
Net Borrowing	6,118,074.3
Shares Insiders	27.68%
Shares Institutions	11.98%
Shares Qo Q	1.02%
Shares Yo Y	5.71%

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	EUR 67.8M
Average Volume	180.8x
Bv Per Share	0.44
CAPEX	EUR -2.1M
Ch1m	-12.21
Ch1w	-5.52
Ch1y	-34.74
Ch3m	-8.99
Ch6m	-41.99
Change	-1.78%
Change From Open	0
Close	0.51
Days Gap	-1.78
Depreciation Amortization	8,832,355.6
EBIT	EUR 7.7M
EBITDA	EUR 16.3M
EPS	EUR 0.03
F Score	5
FCF	EUR 75.6M
FCF EV Yield	42.28x
Financing CF	-8,641,570
Fiscal Year End	December
Founded	2,015
Goodwill	34,075,334.5
Graham Number	0.48499
Graham Upside	-2.22
Income Tax	EUR -1.1M
Investing CF	-109,138,371
Is Primary Listing	0
Last Report Date	2025-12-31
Lynch Fair Value	EUR 0.65
Lynch Upside	30.48
Ma150	0.69
Ma150ch	-27.67%
Ma20	0.54
Ma20ch	-7.98%
Net CF	-40,338,243
Open	0.5
P FCF Ratio	4.72
P OCF Ratio	4.6
Payment Date	2025-06-18
Ppne	26,763,021.3
Price Date	2026-05-08
Price EBITDA	EUR 21.88
Ptbv Ratio	1.74
Relative Volume	8.94x
Revenue	2,553,450,040x
SBC By Revenue	0.31x
Share Based Comp	7,808,792
Tax By Revenue	-0.04x
Tr6m	-41.99%
Z Score	2.18

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

FRA/B1S dividend yield, growth & safety

Yield, payout sustainability, and the multi-year growth streak.

Dividend yield

+1.8%

$0.01 annual per share

Payout ratio

+33.2%

Share of earnings returned as dividends. Below 60% is generally sustainable.

5Y dividend CAGR

n/a

1 consecutive years of growth

Total shareholder yield

-3.9%

Next ex-dividend date: 2025-05-23

Performance

FRA/B1S stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns FRA/B1S?

Insider, institutional, and short-interest positioning.

Institutional ownership

+12.0%

Share of float held by funds and institutions

Insider ownership

+27.7%

Stake held by company insiders. Higher generally signals alignment.

Short interest

n/a

Float sold short by bearish positioning

Y/Y dilution

+5.7%

Negative means the company is buying back shares.

Technical

FRA/B1S momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

43.2

Neutral momentum band

Price vs 200-day MA

-35.8%

50/200-day relationship not available

Beta (5Y)

n/a

Sensitivity to the broader market

Sharpe ratio

-0.46

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About FRA/B1S

Hub-level FAQ points readers to the deeper analysis pages.

What is the current fra/B1S stock rating?

fra/B1S is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full fra/B1S analysis?

The full report lives at /stocks/fra/B1S/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for fra/B1S?

The latest report frames fra/B1S around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the fra/B1S page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.